Neurogene (NGNE) Enterprise Value (2013 - 2026)

Neurogene has reported Enterprise Value for 14 years, with the latest figure at -$243.2 million in Q1 2026.

• For the quarter ending Q1 2026, Enterprise Value rose 16.89% year-over-year to -$243.2 million; the trailing twelve-month figure through Mar 2026 stood at -$243.2 million (up 16.89% YoY), and the FY2025 full-year result was -$269.0 million, up 13.89% from the prior year.
• Enterprise Value for Q1 2026 stood at -$243.2 million, up from -$269.0 million in the prior quarter.
• The five-year high for Enterprise Value was -$78.5 million in Q3 2023, with the low at -$312.4 million in Q4 2024.
• Historically, Enterprise Value has averaged -$176.1 million across 5 years, with a median of -$153.9 million in 2024.
• Annual changes were most pronounced in 2022 — Enterprise Value jumped 42.43% — and 2023, when it plunged 140.37%.
• Neurogene's Enterprise Value stood at -$82.0 million in 2022, then sank by 140.37% to -$197.2 million in 2023, then sank by 58.45% to -$312.4 million in 2024, then gained by 13.89% to -$269.0 million in 2025, then grew by 9.6% to -$243.2 million in 2026.
• The last three Enterprise Value figures came in at -$243.2 million (Q1 2026), -$269.0 million (Q4 2025), and -$265.4 million (Q3 2025), per Business Quant data.